Hypoxia-induced antizyme inhibitors 2 regulates cisplatin resistance through epithelia-mesenchymal transition pathway in non-small cell lung cancer
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 69, 102048
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Planning Project of Fuzhou (2019-SZ-58)
This publication has 30 references indexed in Scilit:
- Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) PatientsPLOS ONE, 2012
- Drug Resistance and Its Significance for Treatment Decisions in Non-Small-Cell Lung CancerCurrent Oncology, 2012
- The tumor microenvironment is a dominant force in multidrug resistanceDrug Resistance Updates, 2012
- Antizyme inhibitor 2: molecular, cellular and physiological aspectsAmino Acids, 2009
- Hypoxia-Mediated Induction of the Polyamine System Provides Opportunities for Tumor Growth Inhibition by Combined Targeting of Vascular Endothelial Growth Factor and Ornithine DecarboxylaseCancer Research, 2008
- Hypoxia-Inducible Factors, Stem Cells, and CancerCell, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007
- A perspective of polyamine metabolismBiochemical Journal, 2003
- Expression of a Novel Human Ornithine Decarboxylase-like Protein in the Central Nervous System and TestesBiochemical and Biophysical Research Communications, 2001
- Identification of Differentially Expressed Genes in Normal and Tumor Human Gastric TissueGenomics, 2000